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Abstract 
Background: The association between triglyceride glucose (TyG) index and coronary atherosclerotic change remains 
unclear. We aimed to evaluate the association between TyG index and coronary plaque progression (PP) using serial 
coronary computed tomography angiography (CCTA).
Methods: A total of 1143 subjects (aged 60.7 ± 9.3 years, 54.6% male) who underwent serial CCTA with available 
data on TyG index and diabetic status were analyzed from The Progression of AtheRosclerotic PlAque DetermIned by 
Computed TomoGraphic Angiography IMaging (PARADIGM) registry. PP was defined as plaque volume (PV)  (mm3) 
at follow‑up minus PV at index > 0. Annual change of PV  (mm3/year) was defined as PV change divided by inter‑scan 
period. Rapid PP was defined as the progression of percent atheroma volume (PV divided by vessel volume multiplied 
by 100) ≥ 1.0%/year.
Results: The median inter‑scan period was 3.2 (range 2.6–4.4) years. All participants were stratified into three groups 
based on TyG index tertiles. The overall incidence of PP was 77.3%. Baseline total PV (group I [lowest]: 30.8 (0.0–117.7), 
group II: 47.2 (6.2–160.4), and group III [highest]: 57.5 (8.4–154.3); P < 0.001) and the annual change of total PV (group 
I: 5.7 (0.0–20.2), group II: 7.6 (0.5–23.5), and group III: 9.4 (1.4–27.7); P = 0.010) were different among all groups. The 
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Background
Coronary artery disease (CAD) is a leading cause of mor-
bidity and mortality worldwide [1]. It is important to 
understand the coronary atherosclerotic progression for 
the prevention of adverse cardiovascular (CV) events. 
Numerous previous studies have suggested the significant 
role of insulin resistance (IR) in the development of CAD 
[2–4]. Recently, the triglyceride glucose (TyG) index has 
been suggested to be a reliable surrogate marker of IR [5–
7]. Several cross-sectional studies have reported that TyG 
index is associated with CAD, especially with coronary 
artery calcification (CAC) [8, 9]. However, longitudinal 
data on the association between TyG index and coronary 
plaque progression (PP) is scarce. Coronary computed 
tomography angiography (CCTA) is a well-established 
non-invasive imaging tool with high diagnostic perfor-
mance for coronary atherosclerosis and predictive value 
for adverse CV events [10–13]. Therefore, we aimed to 
examine the association between baseline TyG index and 
coronary PP using serial CCTA.
Methods
Study design and populations
The Progression of AtheRosclerotic PlAque Deter-
mIned by Computed TomoGraphic Angiography IMag-
ing (PARADIGM) is a prospective, international, and 
multicenter observational registry designed to evaluate 
associations between clinical variables and coronary ath-
erosclerotic changes using serial CCTA [14]. Between 
2003 and 2015, 2252 consecutive subjects underwent 
serial CCTA at 13 centers in 7 countries. Among these 
subjects, 1143 subjects with available information on 
TyG index and diabetic status were included in the pre-
sent study. The characteristics of coronary plaques in all 
participants were categorized based on the TyG index 
tertile. TyG index was calculated as ln [fasting triglycer-
ides (mg/dL) × fasting glucose (mg/dL)/2]. Diabetes was 
defined as treatment with oral hypoglycemic agent or 
insulin or fasting blood glucose (FBG) ≥ 126 mg/dL. The 
institutional review boards approved this study at each 
site.
Acquisition and interpretation of CCTA 
All data acquisition and post-processing of CCTA were 
in accordance with the Society of Cardiovascular Com-
puted Tomography guidelines [15, 16]. CCTA was per-
formed with a ≥ 64-detector row scanner at all centers. 
All datasets from each center were transferred to an 
offline workstation for analysis with a semi-automated 
plaque analysis software (QAngioCT Research Edi-
tion v2.1.9.1; Medis Medical Imaging Systems, Leiden, 
the Netherlands) using manual correction. Segments 
with diameter ≥ 2  mm were evaluated using a modified 
17-segment American Heart Association model [16]. 
Regardless of the presence of atherosclerotic plaques, 
plaque volume (PV)  (mm3) of every coronary segment 
was obtained and summated to generate total PV per 
patient. Coronary plaques were further classified by com-
position according to the pre-defined intensity cut-offs in 
Hounsfield units (HU) for calcified plaques (≥ 351 HU), 
fibrous plaques (131–350 HU), fibro-fatty plaques (31–
130 HU), and necrotic cores (-30 to 30 HU) [17, 18]. For 
comparing longitudinal CCTA images, all baseline and 
follow-up coronary segments were registered together 
with fiduciary landmarks, including the distance from the 
ostia or branch vessel take-offs. PV change was defined as 
plaque volume at follow-up CCTA minus plaque volume 
at baseline CCTA. Annual change of PV  (mm3/year) was 
defined as total PV change divided by inter-scan period. 
Moreover, normalized total atheroma volume  (TAVnorm) 
 (mm3) was defined as total PV divided by vessel length, 
multiplied by the mean participants’ vessel length. 
Annual change of  TAVnorm  (mm3/year) was defined as 
 TAVnorm divided by the inter-scan period. While total 
percent atheroma volume  (PAVtotal) (%) was defined as 
PV divided by vessel volume, multiplied by 100, annual 
change of  PAVtotal (%/year) was defined as total PAV 
divided by inter-scan period, and plaque progression (PP) 
was defined as the difference in plaque volume between 
follow-up and baseline CCTA > 0. Further, rapid PP (%/
year) was defined as an annual progression of PAV ≥ 1.0% 
[19, 20]. Representative CCTA images are presented in 
Fig. 1.
risk of PP (odds ratio [OR] 1.648; 95% confidence interval [CI] 1.167–2.327; P = 0.005) and rapid PP (OR 1.777; 95% CI 
1.288–2.451; P < 0.001) was increased in group III compared to that in group I. TyG index had a positive and significant 
association with an increased risk of PP and rapid PP after adjusting for confounding factors.
Conclusion: TyG index is an independent predictive marker for the progression of coronary atherosclerosis.
Clinical registration ClinicalTrials.gov NCT02803411
Keywords: Triglyceride glucose index, Coronary artery disease, Atherosclerosis, Coronary computed tomography 
angiography
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Statistical analysis
Continuous variables are expressed as mean ± SD or 
medians and interquartile range, while categorical vari-
ables are presented as absolute values and proportions. 
Continuous variables were compared using an independ-
ent t test or the Mann–Whitney U-test, as appropriate 
and categorical variables were compared using the χ2-test 
or Fisher’s exact test, as appropriate. Coronary character-
istics across TyG index tertiles were compared using one-
way analysis of variance or the Kruskal–Wallis test for 
continuous variables, as appropriate. Univariate logistic 
regression analysis was performed to evaluate the associ-
ation between clinical variables and coronary PP. Further, 
multivariate logistic regression analyses were performed 
to identify the independent impact of TyG index on coro-
nary PP. Variables with P < 0.05 in the univariate logistic 
regression analysis were considered confounding vari-
ables and entered into the multivariate logistic regression 
models, except the individual component of TyG index. 
All statistical analyses were performed using the Statis-
tical Package for the Social Sciences version 19 (SPSS, 
Chicago, Illinois). A P value < 0.05 was considered statis-
tically significant for all analyses.
Results
Baseline characteristics
The mean age of the 1143 participants (624 male, 54.6%) 
was 60.7 ± 9.3  years. Median inter-scan period was 3.2 
(range, 2.6–4.4) years. Coronary PP was observed in 
883 (77.3%) participants during follow-up. The clinical 
characteristics of participants according to PP are pre-
sented in Table 1. Age, systolic blood pressure (BP), body 
mass index (BMI), serum triglyceride and FBG levels, 
prevalence of male sex, hypertension, diabetes, hyper-
lipidemia, and the use of aspirin, angiotensin-converting 
enzyme inhibitor (ACEI)/angiotensin receptor blocker 
(ARB), and statin were significantly higher in subjects 
with PP than in those without it. Subjects with PP had 
significantly lower levels of high-density lipoprotein cho-
lesterol (HDL-C) than those without PP. TyG index val-
ues were higher in subjects with PP than in those without 
it (8.85 ± 0.60 vs. 8.69 ± 0.55; P < 0.001).
Comparison of baseline PV and annual change of PV 
according to TyG index tertile
Baseline total PV  (mm3) was as follows: group I [low-
est]: 30.8 (0.0–117.7), group II: 47.2 (6.2–160.4), and 
Fig. 1 Representative CCTA images. CCTA coronary computed tomography angiography, TyG triglyceride glucose
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group III [highest]: 57.5 (8.4–154.3), P < 0.001. Base-
line  TAVnorm values were as follows: group I, 33.0 (0.0–
122.3); group II, 54.1 (7.4–192.3); and group III, 61.2 
(9.5–165.6); P = 0.001.  PAVtotal was as follows: group I, 
1.6 (0.0–6.1); group II: 2.8 (0.4–8.8); and group III: 3.0 
(0.5–8.1); P = 0.001. There were significant differences 
among the TyG index tertile groups at baseline. Regard-
ing coronary plaque subtypes, there was a significant 
difference in the fibrous, fibrous-fatty, necrotic-core, 
and dense calcium PVs among all groups at baseline. 
During follow-up, the annual change of the total PV was 
as follows: group I, 5.7 (0.0–20.2); group II, 7.6 (0.5–
23.5); and group III, 9.4 (1.4–27.7); P = 0.0101; 2) and of 
 TAVnorm was as follows: group I, 6.2 (0.0–19.9); group II, 
7.8 (0.5–25.4); and group III, 9.3 (1.7–31.2); P = 0.005. 
 PAVtotal [group I: 0.3 (0.0–0.9), group II: 0.4 (0.0–1.3), 
and group III: 0.5 (0.1–1.4); P = 0.006] was different 
among all the groups. There was a significant difference 
in the annual change of fibrous and dense calcium PVs 
(Table 2).
Association of clinical variables with coronary 
atherosclerotic change
Age (odds ratio [OR] 1.031; 95% confidence interval 
[CI] 1.016–1.047; P < 0.001), male sex (OR 1.490; 95% CI 
1.129–1.967; P = 0.005), systolic BP (OR 1.012; 95% CI 
1.003–1.022; P = 0.012), BMI (OR 1.077; 95% CI 1.026–
1.130; P = 0.003), and HDL-C (OR 0.987; 95% CI 0.976–
0.998; P = 0.017) were associated with coronary PP. 
Among the TyG tertile groups, PP risk was increased in 
group III compared with that in group I (OR 1.648; 95% 
CI 1.167–2.327; P = 0.005) (Table 3).
Subgroup analysis for the relationship of TyG index 
with coronary PP
Figure  2 shows the subgroup analysis of the estimated 
OR of TyG index for coronary PP. The TyG index was 
significantly associated with an increased risk of PP in 
subgroups of aged < 65  years (OR 1.584; 95% CI 1.190–
2.109; P = 0.002), females (OR 2.061; 95% CI 1.435–2.961; 
P < 0.001), as well as those without hypertension (OR 
1.762; 95% CI 1.249–2.484; P = 0.001), and diabetes (OR 
Table 1 Baseline characteristics
Values are presented as mean ± standard deviation or number (%)
ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, BMI body mass index, BP blood pressure, FBG fasting blood glucose, HDL-C high-
density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TyG triglyceride glucose
Total (n = 1143) PP (−) (n = 260) PP (+) (n = 883) P
Age, years 60.7 ± 9.3 58.7 ± 9.6 61.3 ± 9.1 < 0.001
Male, n (%) 624 (54.6) 122 (46.9) 502 (56.9) 0.005
Systolic BP, mmHg 126.1 ± 16.6 123.7 ± 16.3 126.8 ± 16.6 0.011
Diastolic BP, mmHg 77.0 ± 10.6 75.9 ± 11.1 77.3 ± 10.5 0.079
BMI, kg/m2 24.8 ± 3.0 24.3 ± 3.0 25.0 ± 3.0 0.002
BMI ≥ 25.0 kg/m2, n (%) 493 (43.9) 97 (37.5) 396 (45.8) 0.017
Hypertension, n (%) 674 (59.0) 123 (47.3) 551 (62.5) < 0.001
Diabetes, n (%) 319 (27.9) 48 (18.5) 271 (30.7) < 0.001
Hyperlipidemia, n (%) 381 (33.3) 69 (26.5) 312 (35.4) 0.008
Current smoking, n (%) 213 (18.6) 42 (16.2) 171 (19.4) 0.239
Medications, n (%)
 Aspirin 555 (48.6) 107 (41.2) 448 (50.8) 0.006
 Beta blocker 353 (31.0) 81 (31.2) 272 (30.9) 0.940
 ACEI/ARB 389 (34.2) 67 (25.9) 332 (36.6) 0.001
 Statin 520 (45.5) 89 (34.2) 431 (49.5) < 0.001
 Insulin therapy 33 (2.9) 5 (2.0) 28 (3.2) 0.294
 Total cholesterol, mg/dL 182.6 ± 38.4 184.4 ± 39.6 182.0 ± 38.1 0.393
 Triglyceride, mg/dL 143.3 ± 83.1 132.8 ± 73.9 146.4 ± 85.4 0.020
 HDL‑C, mg/dL 48.7 ± 12.3 50.3 ± 12.8 48.2 ± 12.1 0.016
 LDL‑C, mg/dL 111.5 ± 34.1 113.5 ± 34.2 110.9 ± 34.0 0.289
 Creatinine, mg/dL 1.01 ± 0.67 0.96 ± 0.47 1.01 ± 0.72 0.233
 FBG, mg/dL 110.7 ± 35.0 104.2 ± 28.6 112.7 ± 36.5 < 0.001
 HbA1c, % 6.46 ± 1.27 6.26 ± 1.19 6.51 ± 1.28 0.067
 TyG index 8.81 ± 0.59 8.69 ± 0.55 8.85 ± 0.60 < 0.001
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1.473; 95% CI 1.091–1.990; P = 0.012). The same associa-
tion was observed with hyperlipidemia (OR 1.546; 95% 
CI 1.151–2.076; P = 0.004), BMI ≥ 25.0 kg/m2 (OR 1.564; 
95% CI 1.134–2.157; P = 0.006), and current smoking sta-
tus (OR 1.569; 95% CI 1.193–2.064; P = 0.001).
TyG index on the risk of coronary PP
The results of multiple logistic regression models for the 
association between TyG index and PP risk are presented 
in Table 4. Increased TyG index values were significantly 
related to an increased risk of PP after adjusting for other 
confounding variables. After adjusting for traditional CV 
risk factors, TyG index was associated with coronary PP 
(OR 1.308; 95% CI 1.004–1.703; P = 0.046) (Additional 
file  1: Table  S1). TyG index was particularly associated 
with the calcified PP among coronary plaque sub-types 
(Additional file  2: Table  S2). Regarding rapid coronary 
PP, multivariate logistic regression analysis showed that 
the risk of rapid PP was increased in group III (OR 1.557; 




To the best our knowledge, this is first study to evalu-
ate the longitudinal quantitative changes of coronary 
Table 2 Baseline and changes in the coronary plaque characteristics
Values are presented as median (interquartile range)
PAVtotal total percent atheroma volume, TAVnorm normalized total atheroma volume, TyG triglyceride glucose
Total (n = 1143) TyG index tertiles P
I (lowest) 7.20–8.53 
(n = 382)
II 8.54–9.02 (n = 388) III (highest) 9.03–10.84 
(n = 373)
At baseline
 Plaque volume  (mm3)
  Total 44.1 (3.5–139.6) 30.8 (0.0–117.7) 47.2 (6.2 −160.4) 57.5 (8.4–154.3) < 0.001
  Fibrous 20.3 (0.8–59.1) 13.7 (0.0–49.7) 22.5 (2.9–67.3) 24.3 (3.8–64.4) 0.001
  Fibrous‑fatty 3.5 (0.0–23.4) 1.4 (0.0–14.8) 3.6 (0.0–25.3) 6.1 (0.0–31.8) < 0.001
  Necrotic‑core 0.0 (0.0–1.5) 0.0 (0.0–0.7) 0.0 (0.0–1.6) 0.1 (0.0–2.4) < 0.001
  Dense calcium 6.4 (0.0–38.1) 2.8 (0.0–33.5) 8.0 (0.0–41.2) 8.3 (0.0–36.5) 0.027
TAVnorm  (mm
3) 47.6 (2.6–151.5) 33.0 (0.0–122.3) 54.1 (7.4–192.3) 61.2 (9.5–165.6) 0.001
PAVtotal (%) 2.5 (0.1–7.7) 1.6 (0.0–6.1) 2.8 (0.4–8.8) 3.0 (0.5–8.1) 0.001
Annual change
 Plaque volume  (mm3/year)
  Total 7.6 (0.5–22.2) 5.7 (0.0–20.2) 7.6 (0.5–23.5) 9.4 (1.4–27.7) 0.010
  Fibrous 1.9 (0.0–8.6) 1.1 (0.0–6.9) 1.9 (0.0–8.7) 2.8 (0.0–9.8) 0.022
  Fibrous‑fatty 0.0 (‑0.8–1.4) 0.0 (‑0.5–0.9) 0.0 (‑0.9–1.3) 0.0 (‑1.0–2.3) 0.341
  Necrotic‑core 0.0 (0.0–0.1) 0.0 (0.0–0.0) 0.0 (0.0–0.1) 0.0 (‑0.1–0.1) 0.659
  Dense calcium 3.4 (0.1–11.7) 2.1 (0.0–8.7) 3.7 (0.3–12.1) 3.9 (0.4–13.3) 0.016
TAVnorm  (mm
3/year) 7.7 (0.4–24.4) 6.2 (0.0–19.9) 7.8 (0.5–25.4) 9.3 (1.7–31.2) 0.005
PAVtotal (%/year) 0.4 (0.0–1.2) 0.3 (0.0–0.9) 0.4 (0.0–1.3) 0.5 (0.1–1.4) 0.006
Table 3 Univariate logistic regression analysis 
for  the  association of  clinical variables with  the  risk 
of coronary PP
BMI body mass index, BP blood pressure, CI confidence interval, FBG fasting 
blood glucose, HbA1c hemoglobin A1c; HDL-C, high-density lipoprotein 
cholesterol; LDL-C, low-density lipoprotein cholesterol; OR, odds ratio; TyG, 
triglyceride glucose
Variables OR (95% CI) P
Age, per 1 year 1.031 (1.016–1.047) < 0.001
Male 1.490 (1.129–1.967) 0.005
Systolic BP, per 1 mmHg 1.012 (1.003–1.022) 0.012
Diastolic BP, per 1 mmHg 1.013 (0.999–1.027) 0.079
BMI, per 1 kg/m2 1.077 (1.026–1.130) 0.003
Total cholesterol, per 1 mg/dL 0.998 (0.995–1.002) 0.393
Triglyceride, per 1 mg/dL 1.002 (1.000–1.004) 0.021
HDL‑C, per 1 mg/dL 0.987 (0.976–0.998) 0.017
LDL‑C, per 1 mg/dL 0.998 (0.994–1.002) 0.288
FBG, per 1 mg/dL 1.009 (1.004–1.014) < 0.001
HbA1c, per 1% 1.198 (0.986–1.456) 0.069
TyG index tertiles
 I (lowest) 1 –
 II 1.294 (0.932–1.797) 0.123
 III (highest) 1.648 (1.167–2.327) 0.005
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plaques and their subtypes related to TyG index using 
serial CCTA. This study identified a significant asso-
ciation between TyG index and coronary atherosclero-
sis progression. Previous cross-sectional studies have 
reported a significant relationship between TyG index 
and CAC prevalence [8, 9]. A recent longitudinal study 
revealed that elevated TyG index is independently asso-
ciated with CAC progression [21]. However, this study 
had a retrospective design and included only a Korean 
population, which were limitations. Additionally, con-
sidering that non-calcified plaques might be related to an 
increased risk of acute coronary syndrome events [22], it 
might be important to compare longitudinal changes of 
non-calcified plaques according to TyG index values. In 
the present PARADIGM study, which had a prospective, 
international, and observational design, we identified that 
Fig. 2 Subgroup analysis for the impact of TyG index on coronary PP. TyG triglyceride glucose, PP plaque progression
Table 4 Multiple logistic models for  the  impact of  TyG 
index on coronary PP
BMI body mass index, BP blood pressure, CI confidence interval, HDL-C high-
density lipoprotein cholesterol, OR odds ratio, PP plaque progression, RR relative 
risk, TyG triglyceride glucose
Model 1: Unadjusted
Model 2: Adjusted for age and sex
Model 3: Adjusted for age, sex, systolic BP, BMI, and HDL-C
Variables OR (95% CI) P RR (95% CI) P
TyG index, per 1‑unit increase
 Model 1 1.575 (1.232–2.015) < 0.001 1.103 (1.049–1.160) < 0.001
 Model 2 1.598 (1.250–2.042) < 0.001 1.111 (1.056–1.169) < 0.001
 Model 3 1.409 (1.062–1.869) 0.017 1.083 (1.021–1.150) 0.008
Table 5 Association of  TyG index and  traditional risk 
factors with rapid PP
BMI, body mass index; CI, confidence interval; CV, cardiovascular; OR, odds ratio; 
PP, plaque progression; TyG, triglyceride glucose
Variables Univariate Multivariate
OR (95% CI) P OR (95% CI) P
Age ≥ 65 years 1.836 (1.412–
2.387)

























 I (lowest) 1 – 1 –





 III (highest) 1.777 (1.288–
2.451)
< 0.001 1.557 (1.109–
2.185)
0.011
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the baseline total PV and all subtypes as well as annu-
alized change in total, fibrous, and dense-calcium PV 
increased with increasing TyG index values. In addition, 
the TyG index had a positive association with the annual 
change of total PV,  TAVnorm, and  PAVtotal (Additional 
file 3: Table S3). Even after adjusting for confounding fac-
tors, TyG index was related to the increased risk of PP as 
well as rapid PP. Regarding coronary plaque sub-types, 
TyG index was found to be associated with calcified PP 
after adjusting for traditional CV risk factors in a previ-
ous cross-sectional cohort study [9].
Recent investigations on the longitudinal assessment 
of coronary atherosclerosis
To understand that the coronary atherosclerotic change 
is an important issue in clinical practice, it is well-known 
that diabetes has close association with the prevalence 
and severity of CCTA verified CAD progression [23]. 
Even asymptomatic diabetic patients experience plaque 
progression as well as evolution to overt or silent CAD, 
and an increase in the PV was reported to be associ-
ated with subsequent CV events [24]. In addition, the 
increased duration of diabetes combined with higher 
HbA1c levels deleteriously influences culprit-plaque 
characteristics among diabetic patients who suffered 
acute myocardial infarction [25]. A rapid plaque pro-
gression was specially observed in male patients and in 
patients with typical angina [26]. While helical flow in 
coronary arteries has a protective role against athero-
sclerotic wall thickness growth [27], an intrinsic calcifi-
cation angle, defined as the angle externally projected 
by a vascular calcification, is a novel feature of coronary 
plaque vulnerability and its impact on fibrous cap stress 
is potentiated in more superficial calcifications, adding to 
the destabilizing role of smaller calcifications [28].
Focused issue for the significance of TyG index
It is well-established that IR is a main mechanism in the 
development of type 2 diabetes. A previous PARADIGM 
study identified that individuals with established dia-
betes experienced greater PP, particularly, significantly 
greater progression of adverse plaque formation than 
those without diabetes [29]. In addition, unlike diabetes, 
pre-diabetic condition was not independently associ-
ated with coronary PP in the sub-study of same registry 
[30]; however, although pre-diabetes was defined accord-
ing to the criteria used in previous studies, glycemic 
status was assessed based on only the levels of FBG and 
HbA1c without considering IR status among non-dia-
betic participants. According to the results of a recent 
large cross-sectional cohort study [31], TyG index had 
an independent and positive association with the risk 
of CAD and obstructive CAD in non-diabetic individu-
als; however, glycemic control status reflected in HbA1c 
rather than IR parameters was significantly related to 
the risk of both CAD and obstructive CAD in individu-
als with established diabetes. These results might sup-
port the hypothesis for the different pathogenesis of CAD 
according to diabetic status. In clinical practice, athero-
sclerosis-related adverse events commonly occurred even 
in people with low CV risk burden [32–34]. Thus, early 
detection of the presence and progression of subclinical 
atherosclerosis in this population is important. Recent 
studies have focused on defining useful predictors for 
subclinical atherosclerosis in individuals with low CV 
risk [35, 36]. Interestingly, although the statistical signifi-
cance could be influenced by the sample size of the indi-
vidual subgroup, this study showed that TyG index had 
a significant predictive value for PP in individuals with-
out the traditionally known CV risk factors, especially 
in female subgroup. This result suggests that TyG index 
is a potential surrogate marker for the early detection of 
subclinical atherosclerosis in the absence of CV risk fac-
tors as reported in a recent cross-sectional cohort study 
[37]. Considering the pivotal role of IR in atherosclero-
sis progression by promoting apoptosis of macrophages, 
endothelial cells, and vascular smooth muscle cells [38–
40], further prospective studies with larger sample sizes 
will be necessary to address the predictive value of TyG 
index for subclinical atherosclerosis in individuals with 
low CV risk burden.
Limitations
There are some limitations in the present study. First, 
we only evaluated the association between baseline TyG 
index and coronary atherosclerotic change; longitudinal 
consecutive changes of TyG index during follow-up could 
not be confirmed. Second, the effects of anti-hyperten-
sive and anti-diabetic medications were not controlled 
for because of the observational nature of the study 
design. Third, the homeostatic model assessment of insu-
lin resistance was not analyzed and compared with TyG 
index because insulin levels were not measured in the 
PARADIGM registry. Fourth, we could not confirm the 
TyG index of the small coronary arteries in the present 
study. Fifth, a selection bias might be present because of 
the retrospective inclusion of participants. In addition, 
the results of CCTA at baseline could affect the perfor-
mance of follow-up CCTA. Finally, despite our appli-
cation of strict and standardized criteria for assessing 
CCTA, atherosclerotic findings can be affected by HU 
density. Despite these limitations, this study used serial 
CCTA to estimate coronary PVC and PP according to 
TyG index values in a large multicultural cohort subjects.
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Conclusion
The present study demonstrates the independent asso-
ciation between TyG index values and coronary PP based 
on serial quantitative assessment by CCTA during a rela-
tively short-term period. Further large prospective and 
randomized studies with longer follow-up durations are 
necessary to confirm the results of the present study.
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